Organisation paid for research Program year 2024 Source: CMS Open Payments

Carolina Phase I Research

Neither a doctor nor a teaching hospital

Research payments

$594,815

59 payments

Through program year 2024, Carolina Phase I Research is reported as receiving $594,815 in research payments, across 59 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$20,445	5
2023	Research	$3,407	3
2022	Research	$68,784	7
2021	Research	$8,887	7
2020	Research	$39,608	10
2019	Research	$453,683	27

Breakdown

Who paid Research payments · program years 2019–2024

AbbVie, Inc. $594,815 59 payments

Studies the money was for Research payments · program years 2019–2024

M15-738 $421,036 17 payments
M15-741 $62,605 19 payments
Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinsonx27s Disease $48,034 5 payments
Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson Disease $20,445 5 payments
Parkinsons disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. $10,800 1 payment
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinsons Disease $9,950 1 payment
M15-737 $9,650 1 payment
An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinsons disease $5,321 4 payments
A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinsons disease $3,566 3 payments
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease $1,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.